Who bought NGM? Van I know you did, Unconventional I know you did... We only have two bios in the damn portfolio.... These companies are starting to get bought left and right... UPDATE**--> NGM Biopharmaceuticals price target raised to $38 from $30 at B. Riley 08:20 NGM B. Riley Securities analyst Mayank Mamtani raised the firm's price target on NGM Biopharmaceuticals to $38 from $30 and keeps a Buy rating on the shares following the company's inaugural analyst day. The new target attributes higher value to NGM's earlier stage pipeline and assumes Merck exercising its option in Q1 to extend the collaboration beyond expiration of March, 2022, Mamtani tells investors in a research note.
Hold Off on ROOT Van--- trouble brewing.... Bear Cave says Root Insurance 'misleading investors and consumers' 12/03 ROOT In a short report published on its site that is available only for subscribers, Edwin Dorsey of Bear Cave Research said he sees "problems" at Root Insurance, which the short-seller claims is "misleading investors and consumers."Reference Link
DS- Drive Shack-- ZBRA-- Barcodes for vials AZEK-- Lockup expiring ARCT-- That other vaccine play....
Watch-> Fidelity National Financial, Inc. (FNF) NYSE - Nasdaq Real Time Price. Currency in USD $38.08+0.64 (+1.71%)
VAN ARCT Can be bough there... you agree? Corinne Cardina: Are there any drug developers that may be earlier stages than some of the ones we've mentioned that are taking an approach that could be game-changing? Keith Speights: Yeah, there are a couple that I've really watched, Corinne. One I think you and I have spoken about before -- Vaxart (NASDAQ:VXRT). Vaxart has an early-stage oral tablet. The idea of having a vaccine that you just pop a pill, so to speak, instead of getting stuck with a needle, that would be quite intriguing. Very low market cap there -- below $1 billion. Again, it's early stage, but if they're successful, Vaxart could really take off. Another one, a little plug here, a shameless plug. I'm working on an article that should publish on Saturday. It's about the dark horse to watch, and that dark horse to watch in the coronavirus vaccine race, I think, is Arcturus Therapeutics (NASDAQ:ARCT). Arcuturs has an mRNA vaccine. Pfizer and Moderna have mRNA vaccines, so we've already seen that they can have a really high efficacy. But they have an mRNA single-dose vaccine that's in a phase 1/2 study. They also hope to have a freeze-dried version of it available for phase 3 testing. You've got Arcturus with just checking off all the boxes. Single-dose, which will be wonderful, mRNA, which seems to have very high efficacy, and freeze-dried, which would address some of the ultra-cold storage requirements. Arcturus is one that I really am fascinated by. I'm going to see what happens next and see how the results look. Corinne Cardina: Keith, do you know the ticker for Arcturus? Keith Speights: Yeah. That's ARCT.<___KABOOM_______
van! I'm deep in the woods I don't have access to anything much more than a land line here-- ARCT was that stk that I had along with the one we used CVAC that went through the roof... these are the other guys... (ARCT) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Add to watchlist Visitors trend2W10W9M 113.35+7.34 (+6.92%)<------- what's your bid/ask? As of 9:53A
Cramer blast Off!-- he killed my trade. This was a personal attack. Upon myself. Prediction: He has arturus the vax guys on tonight!!!!!! or ZEBRA.... The AZEK Company Inc. (AZEK) NYSE - Nasdaq Real Time Price. Currency in USD 37.01+1.95 (+5.58%)<------------ Van fade this into Thurs.... As of 9:58AM EST. Market open.
Robin Hood Loves Fake Wood- Arcturus Therapeutics Holdings Inc. (ARCT) NasdaqGM - NasdaqGM Real Time Price. Currency in USD 115.30+9.29 (+8.76%) As of 11:48AM EST. Market open. VAN TAKING THE $2 DAY TRADE BECAUSE YOU DID NOT GET BACK IN TOUCH IF THIS EXPLODES FROM HERE.....
That Sportrac has still not up with a SPAC merge... I wonder if a SPAC run by Billy Bean would be interested... Redbird Capital is a SPAC backed by Billy Beane of Moneyball fame. RBAC--